Excessive Daytime Sleepiness Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Ph

DelveInsight's "Excessive Daytime Sleepiness - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Excessive Daytime Sleepiness market share of the individual therapies, current and forecasted Excessive Daytime Sleepiness market size from 2020 to 2034 segmented by seven major markets. The report also offers current Excessive Daytime Sleepiness therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Excessive Daytime Sleepiness market.
Download our report: https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the excessive daytime sleepiness market report:
Prominent companies working in the excessive daytime sleepiness market are Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Pharma Ltd, XWPharma, Takeda Pharmaceutical, and other.
The Excessive Daytime Sleepiness (EDS) market across the 7MM was valued at approximately USD 6.227 billion in 2023, with growth expected throughout the forecast period (2024-2034). In the United States alone, the EDS market reached USD 4.690 billion in 2023.
The current EDS therapeutic landscape includes several key treatments such as SUNOSI, WAKIX, XYREM, and XYWAV. In 2023, XYREM and WAKIX generated market revenues of USD 1.163 billion and USD 565 million, respectively, across the 7MM.
The prevalence of EDS has risen over the past decade due to advancements in diagnosis and increased awareness. Contributing factors include unhealthy lifestyle choices such as poor diet, lack of exercise, smoking, drug and alcohol abuse, and stress. Despite improvements in diagnostic capabilities, challenges remain due to a lack of standardized guidelines, the non-specific nature of symptoms, and disease variability. Further research into the neurobiology of sleep and wakefulness is needed.
Initial treatment for EDS often involves maintaining good sleep hygiene, with behavioral and non-pharmacological approaches being the first line of management. Pharmacotherapy is typically used as an adjunct, tailored to the specific nature of the disorder.
Approved medications for EDS include PROVIGIL/MODIODAL (modafinil), NUVIGIL (armodafinil), SUNOSI (solriamfetol), WAKIX (pitolisant), XYWAV (a lower sodium alternative to sodium oxybate), and XYREM (sodium oxybate). Most of these are used for EDS related to narcolepsy, though the majority of patients with EDS across the 7MM are those with obstructive sleep apnea (OSA), bipolar disorder, or Parkinson's disease. The focus of drug development has been primarily on narcolepsy, with a robust clinical pipeline in this area and fewer options for other conditions.
There remains an unmet need for affordable therapies that address EDS across a broader patient population. Specifically, there is a gap in treatments for EDS associated with bipolar disorder and Parkinson's disease.
XYWAV, a lower sodium alternative to XYREM, was approved in 2020 and generated USD 1.007 billion in revenue in 2023. This drug is expected to continue growing as it captures the market previously dominated by the now-expired patent of XYREM.
SUNOSI, approved by the US FDA in 2019 for EDS related to OSA, achieved revenues of USD 132 million in 2023, with further growth anticipated.
AXS-12 (reboxetine) is projected to enter the US market by 2025 for EDS in narcolepsy. With the expiration of patents for existing therapies, AXS-12 could establish a strong market presence, reaching peak uptake in its seventh year.
Currently, there are no approved therapies specifically for EDS in Parkinson's disease, and the pipeline for this niche remains limited.

Excessive Daytime Sleepiness Overview
Excessive daytime sleepiness (EDS) is characterized by an overwhelming difficulty in staying awake and alert during daytime hours, often resulting in unintentional sleep or falling asleep at inappropriate times. EDS is commonly linked to a range of health conditions, including metabolic, cardiovascular, neurological, and psychiatric disorders. It is also associated with behaviors reflecting poor sleep habits and sleep debt, which can lead to disability and an increased risk of mortality.

The causes of EDS are diverse, including insufficient sleep, sleep-disordered breathing, circadian rhythm sleep-wake disorders, and central hypersomnolence disorders such as narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome. EDS may also be a symptom of an underlying medical or psychiatric condition. The highest incidence is observed in adolescents, older adults, and shift workers. However, determining the true prevalence of EDS is challenging due to the subjective nature of symptoms, inconsistencies in terminology, and a lack of standardized diagnostic methods.

Quality sleep is crucial for memory consolidation, immune system restoration, and other essential processes. Consequently, inadequate sleep can lead to various symptoms that may not immediately connect to sleep issues. The impact of EDS can be severe, affecting cognitive function, overall health, professional performance, and increasing the risk of motor vehicle accidents. Additionally, EDS has notable social and economic consequences, making it a significant public health concern.

To know more about excessive daytime sleepiness, causes, signs and symptoms, diagnosis, treatment options, visit: https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Excessive Daytime Sleepiness Epidemiological Insights
In 2023, there were approximately 7 million diagnosed cases of excessive daytime sleepiness across the 7MM, with numbers expected to rise throughout the study period (2020-2034) due to increasing prevalence of related conditions.
In the United States alone, DelveInsight estimates that there were around 3.9 million diagnosed cases of excessive daytime sleepiness in 2023. This number is projected to grow by 2034, driven by heightened awareness of the condition, improved differentiation from similar issues like fatigue, and a greater recognition of the impact of lifestyle and mental health factors such as stress and depression.
Excessive Daytime Sleepiness Treatment Market

The evaluation and management of excessive daytime sleepiness involve identifying and treating underlying conditions such as narcolepsy, Parkinson's disease, obstructive sleep apnea (OSA), idiopathic hypersomnia (IH), and bipolar disorder. The primary approach includes supportive care and approved therapies to alleviate symptoms. Supportive treatments commonly used include armodafinil (the R-enantiomer of modafinil), amphetamines, methamphetamines, dextroamphetamine, and methylphenidate.

Treatment often involves central nervous system stimulants, like methylphenidate and modafinil, which are wake-promoting but not related to amphetamines. Recently, the American Academy of Sleep Medicine (AASM) has recommended sodium oxybate as a first-line treatment for excessive daytime sleepiness and cataplexy. Common amphetamine-like stimulants include methylphenidate, methamphetamine, D-amphetamine (all schedule II substances), and mazindol (a schedule IV substance). Standards of practice for narcolepsy often focus on these stimulant treatments.

PROVIGIL (modafinil), introduced by Cephalon in 1999, is used to treat excessive sleepiness associated with narcolepsy, OSA, and shift work disorder (SWD). It is approved in over 30 countries, including France, the UK, Ireland, Italy, and Germany. In January 2007, modafinil was approved in Japan for excessive daytime sleepiness related to narcolepsy, and later for OSA and idiopathic hypersomnia in 2011 and 2020, respectively.

NUVIGIL (armodafinil), the R-isomer of modafinil, was launched by Cephalon in June 2009 and is indicated for excessive sleepiness related to narcolepsy, OSA, and SWD.

SUNOSI (solriamfetol), approved by the US FDA in March 2019, is the first dual-acting dopamine and norepinephrine reuptake inhibitor for excessive daytime sleepiness associated with narcolepsy or OSA. It received EU Marketing Authorization in January 2020 and is the only licensed therapy in Europe for excessive daytime sleepiness in adults with OSA. It is also being evaluated for use in pediatric patients.

Companies such as Axsome Therapeutics and Suven Life Sciences are advancing their lead candidates through various stages of clinical development, aiming to offer new treatments for excessive daytime sleepiness.
Excessive Daytime Sleepiness Market Insights:
In 2023, the total market size for excessive daytime sleepiness across the 7MM was approximately USD 6.2 billion and is expected to grow throughout the forecast period (2024-2034). In the United States alone, the market for excessive daytime sleepiness therapies was valued at USD 4.7 billion in 2023.
The current market is primarily driven by products such as SUNOSI, WAKIX, XYREM, and XYWAV. In 2023, XYREM and WAKIX generated revenues of USD 1.16 billion and USD 565 million, respectively, in the 7MM. XYWAV (calcium, magnesium, potassium, and sodium oxybate), a lower-sodium alternative to XYREM approved in 2020 for narcolepsy-related excessive daytime sleepiness, earned USD 1.01 billion in 2023.
Japan's market for excessive daytime sleepiness was approximately USD 382.8 million in 2023 and is projected to see significant growth by 2034.
AXS-12 (reboxetine) is anticipated to enter the U.S. market for excessive daytime sleepiness in narcolepsy by 2025. With the impending loss of patents for existing therapies, Axsome Therapeutics has the opportunity to make a substantial impact in the market. The drug is expected to gain a moderate share and reach its peak performance by its seventh year.

Promising Therapies in the Excessive Daytime Sleepiness Pipeline
Wakix/ Ozawade (Pitolisant)
Sunosi (Solriamfetol)
FT218 (Sodium Oxybate)
AXS-12 (Reboxetine)
And others
Discover more about Excessive Daytime Sleepiness therapies in the pipeline @ https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Excessive Daytime Sleepiness Market
Bioprojet Pharma
Harmony Biosciences
Jazz Pharmaceuticals
Avadel Pharmaceutical
Axsome Therapeutic
And others
To understand key companies related to the Excessive Daytime Sleepiness Market, get a snapshot of the Excessive Daytime Sleepiness Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Excessive Daytime Sleepiness Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Excessive Daytime Sleepiness Companies: Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, Avadel Pharmaceutical, Axsome Therapeutic, and others
Key Excessive Daytime Sleepiness Pipeline Therapies: Wakix/ Ozawade (Pitolisant), Sunosi (Solriamfetol), FT218 (Sodium Oxybate), AXS-12 (Reboxetine), and others
Therapeutic Assessment: Excessive Daytime Sleepiness current marketed and emerging therapies
Excessive Daytime Sleepiness Market Dynamics: Excessive Daytime Sleepiness market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Excessive Daytime Sleepiness Market Access and Reimbursement
Table of Contents
1. Excessive Daytime Sleepiness Market Key Insights
2. Excessive Daytime Sleepiness Market Report Introduction
3. Excessive Daytime Sleepiness Market Overview at a Glance
4. Excessive Daytime Sleepiness Market Executive Summary
5. Disease Background and Overview
6. Excessive Daytime Sleepiness Treatment and Management
7. Excessive Daytime Sleepiness Epidemiology and Patient Population
8. Patient Journey
9. Excessive Daytime Sleepiness Emerging Drugs
10. 7MM Excessive Daytime Sleepiness Market Analysis
11. Excessive Daytime Sleepiness Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Excessive Daytime Sleepiness Market Drivers
15. Excessive Daytime Sleepiness Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.